

Ingolf Cascorbi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3440596/ingolf-cascorbi-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

228 papers	11,149 citations	56 h-index	97 g-index
260 ext. papers	12,153 ext. citations	4.8 avg, IF	6.11 L-index

#	Paper	IF	Citations
228	Limited Impact of 6-Mercaptopurine on Inflammation-Induced Chemokines Expression Profile in Primary Cultures of Enteric Nervous System. <i>Neurochemical Research</i> , 2021 , 46, 1781-1793	4.6	0
227	High-dose spironolactone lacks effectiveness in treatment of fibromyalgia (RCT). <i>European Journal of Pain</i> , 2021 , 25, 1739-1750	3.7	0
226	Pharmacovigilance-based drug repurposing: The search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 4421-4431	3.8	14
225	Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia. <i>Frontiers in Pharmacology</i> , 2021 , 12, 696960	5.6	6
224	Drug-Drug-Gene Interactions: A Call for Clinical Consideration. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 549-551	6.1	1
223	The serotonin receptor 2A (HTR2A) rs6313 variant is associated with higher ongoing pain and signs of central sensitization in neuropathic pain patients. <i>European Journal of Pain</i> , 2021 , 25, 595-611	3.7	5
222	Involvement of medical students in a surgery congress: impact on learning motivation, decision-making for a career in surgery, and educational curriculum. <i>Wiener Medizinische Wochenschrift</i> , 2021 , 171, 182-193	2.9	0
221	ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021 , 17, 369-396	5.5	11
220	Gliflozins for the Treatment of Congestive Heart Failure and Renal Failure in Type 2 Diabetes. <i>Deutsches Arzteblatt International</i> , 2021 , 118,	2.5	4
219	Interaction of Phytocompounds of with ABCB1 and ABCG2 Efflux Transporters. <i>Molecular Pharmaceutics</i> , 2021 , 18, 1622-1633	5.6	
218	ZFP36L1 plays an ambiguous role in the regulation of cell expansion and negatively regulates CDKN1A in chronic myeloid leukemia cells. <i>Experimental Hematology</i> , 2021 , 99, 54-64.e7	3.1	1
217	Alternative Polyadenylation of ABC Transporters of the C-Family (ABCC1, ABCC2, ABCC3) and Implications on Posttranscriptional Micro-RNA Regulation. <i>Molecular Pharmacology</i> , 2020 , 97, 112-122	4.3	10
216	Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance. <i>Experimental Hematology and Oncology</i> , 2020 , 9, 26	7.8	8
215	Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper. <i>Oncology Research and Treatment</i> , 2020 , 43, 628-636	2.8	22
214	Meta-analysis on outcome-worsening comorbidities of COVID-19 and related potential drug-drug interactions. <i>Pharmacological Research</i> , 2020 , 161, 105250	10.2	21
213	Interaction of herbal products with prescribed medications: A systematic review and meta-analysis. <i>Pharmacological Research</i> , 2019 , 141, 397-408	10.2	25
212	Plan S: A threat to quality of science?. <i>Science</i> , 2019 , 363, 462	33.3	3

211	Implementation and obstacles of pharmacogenetics in clinical practice: An international survey. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2076-2088	3.8	14
210	Linking pre-existing biorepositories for medical research: the PopGen 2.0 Network. <i>Journal of Community Genetics</i> , 2019 , 10, 523-530	2.5	4
209	Implications of genetic variation of common Drug Metabolizing Enzymes and ABC Transporters among the Pakistani Population. <i>Scientific Reports</i> , 2019 , 9, 7323	4.9	12
208	A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. <i>Gastroenterology</i> , 2019 , 156, 1707-1716.e2	13.3	59
207	Transcriptional and Post-Transcriptional Regulation of Duodenal P-Glycoprotein and MRP2 in Healthy Human Subjects after Chronic Treatment with Rifampin and Carbamazepine. <i>Molecular Pharmaceutics</i> , 2019 , 16, 3823-3830	5.6	14
206	Pharmacogenomics education in medical and pharmacy schools: conclusions of a global survey. <i>Pharmacogenomics</i> , 2019 , 20, 643-657	2.6	31
205	4th ESPT Conference: pharmacogenomics and personalized medicine—research progress and clinical implementation. <i>Pharmacogenomics</i> , 2019 , 20, 1063-1069	2.6	1
204	Germline variants in cancer therapy. 2019 , 2, 18-30		
203	Retinoic acid-induced survival effects in SH-SY5Y neuroblastoma cells. <i>Journal of Cellular Biochemistry</i> , 2019 , 120, 5974-5986	4.7	9
202	Dysregulation of Mucosal Membrane Transporters and Drug-Metabolizing Enzymes in Ulcerative Colitis. <i>Journal of Pharmaceutical Sciences</i> , 2019 , 108, 1035-1046	3.9	23
201	SIGMA-1 Receptor Gene Variants Affect the Somatosensory Phenotype in Neuropathic Pain Patients. <i>Journal of Pain</i> , 2019 , 20, 201-214	5.2	8
200	MicroRNA-655-3p regulates Echinacea purpurea mediated activation of ABCG2. <i>Xenobiotica</i> , 2018 , 48, 1050-1058	2	8
199	The Pharmacogenetics of Immune-Modulating Therapy. <i>Advances in Pharmacology</i> , 2018 , 83, 275-296	5.7	2
198	In Reply. <i>Deutsches A&#x0308;rztblatt International</i> , 2018 , 115, 713	2.5	
197	Key Learning Outcomes for Clinical Pharmacology and Therapeutics Education in Europe: A Modified Delphi Study. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 104, 317-325	6.1	30
196	Drug Hypersensitivity. <i>Deutsches A&#x0308;rztblatt International</i> , 2018 , 115, 501-512	2.5	18
195	The Nomenclature, Definition and Distinction of Types of Shock. <i>Deutsches A&#x0308;rztblatt International</i> , 2018 , 115, 757-768	2.5	35
194	The Neurophysiology and Treatment of Motion Sickness. <i>Deutsches A&#x0308;rztblatt International</i> , 2018 , 115, 687-696	2.5	26

193	Crosstalk control and limits of physiological c-Jun N-terminal kinase activity for cell viability and neurite stability in differentiated PC12 cells. <i>Molecular and Cellular Neurosciences</i> , 2017 , 82, 12-22	4.8	1
192	Neurodegenerative effects of azithromycin in differentiated PC12 cells. <i>European Journal of Pharmacology</i> , 2017 , 809, 1-12	5.3	9
191	Clinically Relevant Multidrug Transporters Are Regulated by microRNAs along the Human Intestine. <i>Molecular Pharmaceutics</i> , 2017 , 14, 2245-2253	5.6	24
190	Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. <i>Gastroenterology</i> , 2017 , 152, 1078-1089	13.3	137
189	Pharmakogenetik. <i>Medizinische Genetik</i> , 2017 , 29, 389-396	0.5	1
188	Activation of the cell membrane angiotensin AT2 receptors in human leiomyosarcoma cells induces differentiation and apoptosis by a PPAR α dependent mechanism. <i>Neoplasma</i> , 2017 , 64, 395-405	3.3	6
187	Hematopoietic stem cell involvement in positive ALL as a potential mechanism of resistance to blinatumomab therapy. <i>Blood</i> , 2017 , 130, 2027-2031	2.2	52
186	Neuroprotective effects of AT1 receptor antagonists after experimental ischemic stroke: what is important?. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2017 , 390, 949-959	3.4	8
185	Advances and challenges in hereditary cancer pharmacogenetics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 73-82	5.5	7
184	Pioglitazone induces cell growth arrest and activates mitochondrial apoptosis in human uterine leiomyosarcoma cells by a peroxisome proliferator-activated receptor β independent mechanism. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2017 , 390, 37-48	3.4	7
183	Short Report: TRPV1-polymorphism 1911 A>G alters capsaicin-induced sensory changes in healthy subjects. <i>PLoS ONE</i> , 2017 , 12, e0183322	3.7	10
182	MicroRNA-212/ABCG2-axis contributes to development of imatinib-resistance in leukemic cells. <i>Oncotarget</i> , 2017 , 8, 92018-92031	3.3	14
181	miRNA-187-3p-Mediated Regulation of the KCNK10/TREK-2 Potassium Channel in a Rat Epilepsy Model. <i>ACS Chemical Neuroscience</i> , 2016 , 7, 1585-1594	5.7	12
180	Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes. <i>Pharmacogenomics</i> , 2016 , 17, 367-74	2.6	16
179	Length variants of the ABCB1 3'UTR and loss of miRNA binding sites: possible consequences in regulation and pharmacotherapy resistance. <i>Pharmacogenomics</i> , 2016 , 17, 327-40	2.6	17
178	A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics. <i>PLoS ONE</i> , 2016 , 11, e0162866	3.7	66
177	Pharmacogenetics and Predictive Testing of Drug Hypersensitivity Reactions. <i>Frontiers in Pharmacology</i> , 2016 , 7, 396	5.6	21
176	HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury. <i>Pharmacogenetics and Genomics</i> , 2016 , 26, 218-24	1.9	50

175	Pharmacogenomic or -epigenomic biomarkers in drug treatment: Two sides of the same medal?. <i>Clinical Pharmacology and Therapeutics</i> , 2016 , 99, 478-80	6.1	16
174	Targeting gene expression during the early bone healing period in the mandible: A base for bone tissue engineering. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2015 , 43, 1452-60	3.6	3
173	TRP Gene Polymorphism and Disease Risk 2015 , 59-87		
172	SOX11 identified by target gene evaluation of miRNAs differentially expressed in focal and non-focal brain tissue of therapy-resistant epilepsy patients. <i>Neurobiology of Disease</i> , 2015 , 77, 127-40	7.5	33
171	Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 75, 207-14	3.5	17
170	Which Genetic Determinants Should be Considered for Tacrolimus Dose Optimization in Kidney Transplantation? A Combined Analysis of Genes Affecting the CYP3A Locus. <i>Therapeutic Drug Monitoring</i> , 2015 , 37, 288-95	3.2	36
169	MicroRNAs and their relevance to ABC transporters. <i>British Journal of Clinical Pharmacology</i> , 2014 , 77, 587-96	3.8	70
168	Functional characterization of protein variants encoded by nonsynonymous single nucleotide polymorphisms in MARC1 and MARC2 in healthy Caucasians. <i>Drug Metabolism and Disposition</i> , 2014 , 42, 718-25	4	6
167	Identification and characterization of a defective CYP3A4 genotype in a kidney transplant patient with severely diminished tacrolimus clearance. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 95, 416-22	6.1	30
166	Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014 , 10, 1337-54	5.5	89
165	Functional gene variants of CYP3A4. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 96, 340-8	6.1	146
164	Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. <i>Nature Communications</i> , 2014 , 5, 4757	17.4	118
163	Genetic variants may play an important role in mRNA-miRNA interaction: evidence for haplotype-dependent downregulation of ABCC2 (MRP2) by miRNA-379. <i>Pharmacogenetics and Genomics</i> , 2014 , 24, 283-91	1.9	27
162	Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1). <i>Clinical Cancer Research</i> , 2014 , 20, 985-94	12.9	45
161	Association of ATP-binding cassette transporter variants with the risk of Alzheimer's disease. <i>Pharmacogenomics</i> , 2013 , 14, 485-94	2.6	34
160	A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer. <i>Investigational New Drugs</i> , 2013 , 31, 661-8	4.3	6
159	Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme. <i>BMC Cancer</i> , 2013 , 13, 617	4.8	35
158	P-glycoprotein (MDR1/ABCB1) 2013 , 271-293		1

157	Challenges in pharmacogenetics. <i>European Journal of Clinical Pharmacology</i> , 2013 , 69 Suppl 1, 17-23	2.8	11
156	Correspondence (reply): In Reply. <i>Deutsches A&#x0308;rzteblatt International</i> , 2013 , 110, 133	2.5	
155	miRNAs as mediators of drug resistance. <i>Epigenomics</i> , 2012 , 4, 369-81	4.4	56
154	Pharmacogenetics of Phase II Drug Metabolizing Enzymes 2012 , 81-100		
153	Drug interactions--principles, examples and clinical consequences. <i>Deutsches A&#x0308;rzteblatt International</i> , 2012 , 109, 546-55; quiz 556	2.5	81
152	Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients. <i>European Journal of Clinical Pharmacology</i> , 2012 , 68, 389-95	2.8	23
151	Stellungnahme der Sektion Schock der DIVI zur Schocklage. <i>Notarzt</i> , 2012 , 28, 12-16	0.3	1
150	Highlights from the latest articles in breast cancer pharmacogenomics. <i>Pharmacogenomics</i> , 2012 , 13, 645-9	2.6	
149	Elimination half-life of anti-Müllerian hormone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 2160-3	5.6	37
148	OpenVigil--free eyeballs on AERS pharmacovigilance data. <i>Nature Biotechnology</i> , 2012 , 30, 137-8	44.5	25
147	Differential expression and functionality of TRPA1 protein genetic variants in conditions of thermal stimulation. <i>Journal of Biological Chemistry</i> , 2012 , 287, 27087-94	5.4	26
146	MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression. <i>Pharmacogenetics and Genomics</i> , 2012 , 22, 198-205	1.9	62
145	P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. <i>Handbook of Experimental Pharmacology</i> , 2011 , 261-83	3.2	135
144	Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy. <i>Pharmacogenetics and Genomics</i> , 2011 , 21, 624-30	1.9	40
143	Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function. <i>Pharmacogenomics Journal</i> , 2011 , 11, 25-34	3.5	62
142	Antimicrobial peptides and proteins of the horse--insights into a well-armed organism. <i>Veterinary Research</i> , 2011 , 42, 98	3.8	44
141	Analysis of alternative promoter usage in expression of HSD11B1 including the development of a transcript-specific quantitative real-time PCR method. <i>Chemico-Biological Interactions</i> , 2011 , 191, 104-12	5	11
140	Clinical implementation of pharmacogenetics: a nonrepresentative explorative survey to participants of WorldPharma 2010. <i>Pharmacogenomics</i> , 2011 , 12, 1051-9	2.6	11

139	Down-regulation of ATP-binding cassette C2 protein expression in HepG2 cells after rifampicin treatment is mediated by microRNA-379. <i>Molecular Pharmacology</i> , 2011 , 80, 314-20	4.3	66
138	Transient receptor potential channel polymorphisms are associated with the somatosensory function in neuropathic pain patients. <i>PLoS ONE</i> , 2011 , 6, e17387	3.7	102
137	Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. <i>Journal of Clinical Psychiatry</i> , 2011 , 72, 458-63	4.6	98
136	Pharmakodynamik 2011 , 15-43		1
135	Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2010 , 107, 570-6	3.1	16
134	ABC transporters in drug-refractory epilepsy: limited clinical significance of pharmacogenetics?. <i>Clinical Pharmacology and Therapeutics</i> , 2010 , 87, 15-8	6.1	28
133	Safe and effective medicines for all: is personalized medicine the answer?. <i>Expert Review of Clinical Pharmacology</i> , 2010 , 3, 627-37	3.8	0
132	Pharmacogenetics of ATP-binding cassette transporters and clinical implications. <i>Methods in Molecular Biology</i> , 2010 , 596, 95-121	1.4	52
131	Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: an open-label, prospective study of long-term administration in adults. <i>Clinical Therapeutics</i> , 2010 , 32, 347-56	3.5	3
130	Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 1947-56	4.5	40
129	Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 -24C>T polymorphism in young and adult patients with epilepsy. <i>Pharmacogenetics and Genomics</i> , 2009 , 19, 353-62	1.9	79
128	Decreased sigmoidal ABCB1 (P-glycoprotein) expression in ulcerative colitis is associated with disease activity. <i>Pharmacogenomics</i> , 2009 , 10, 1941-53	2.6	39
127	Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: a possible role of intestinal CYP3A4 expression. <i>Clinical Pharmacology and Therapeutics</i> , 2008 , 84, 43-6	6.1	28
126	Association of ABCB1 genetic variants 3435C>T and 2677G>T to ABCB1 mRNA and protein expression in brain tissue from refractory epilepsy patients. <i>Epilepsia</i> , 2008 , 49, 1555-61	6.4	33
125	Pharmacogenomics in acute coronary syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 363-76	4	2
124	Major increase of quetiapine steady-state plasma concentration following co-administration of clarithromycin: confirmation of the pharmacokinetic interaction potential of quetiapine. <i>Pharmacopsychiatry</i> , 2008 , 41, 258-9	2	10
123	Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol. <i>Pharmacogenetics and Genomics</i> , 2008 , 18, 357-65	1.9	73
122	Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens. <i>Pharmacogenomics Journal</i> , 2007 , 7, 325-32	3.5	52

121	CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. <i>Clinical Pharmacology and Therapeutics</i> , 2007 , 81, 228-34	6.1	105
120	MDR1-P-Glycoprotein (ABCB1) Mediates Transport of Alzheimer® amyloid-beta peptides--implications for the mechanisms of Abeta clearance at the blood-brain barrier. <i>Brain Pathology</i> , 2007 , 17, 347-53	6	189
119	A clinical trial on absorption and N-acetylation of oral and rectal mesalazine. <i>European Journal of Clinical Investigation</i> , 2007 , 37, 558-65	4.6	12
118	Pharmakogenetik in der Kardiologie. <i>Kardiologe</i> , 2007 , 1, 272-280	0.6	
117	Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. <i>Pharmacogenomics Journal</i> , 2007 , 7, 56-65	3.5	136
116	Myeloperoxidase G-463A polymorphism and lung cancer: a HuGE genetic susceptibility to environmental carcinogens pooled analysis. <i>Genetics in Medicine</i> , 2007 , 9, 67-73	8.1	42
115	Risk of coronary artery disease as influenced by variants of the human endothelin and endothelin-converting enzyme genes. <i>Pharmacogenetics and Genomics</i> , 2007 , 17, 77-83	1.9	10
114	Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs 2006 , 112, 457-73		274
113	No benefit of 3,4-diaminopyridine in essential tremor: a placebo-controlled crossover study. <i>Neurology</i> , 2006 , 66, 1753-5	6.5	12
112	The ATP-binding cassette transporter ABCG2 (BCRP), a marker for side population stem cells, is expressed in human heart. <i>Journal of Histochemistry and Cytochemistry</i> , 2006 , 54, 215-21	3.4	77
111	Genetic basis of toxic reactions to drugs and chemicals. <i>Toxicology Letters</i> , 2006 , 162, 16-28	4.4	66
110	Multidrug resistance 1 genotype and disposition of budesonide in early primary biliary cirrhosis. <i>Liver International</i> , 2006 , 26, 285-90	7.9	4
109	Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. <i>British Journal of Clinical Pharmacology</i> , 2006 , 61, 440-50	3.8	34
108	Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 79, 206-17	6.1	81
107	OV-A-2. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 79, P34-P34	6.1	
106	A LC-MS/MS method to quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006 , 830, 143-50	3.2	60
105	Kardiopulmonale ReanimationÄPR. <i>Intensivmedizin Und Notfallmedizin</i> , 2006 , 43, 446-451		1
104	Replication of Genetic Markers Associated with Clozapine-Induced Agranulocytosis.. <i>Blood</i> , 2006 , 108, 1280-1280	2.2	

103	Comparison of extremes. Approach provides evidence against the modifying role of NAT2 polymorphism in lung cancer susceptibility. <i>Cancer Letters</i> , 2005 , 221, 177-83	9.9	19
102	Influence of an insertion variant in the 5'UTR of the endothelin-1 gene on orthostatic intolerance. <i>American Journal of the Medical Sciences</i> , 2005 , 330, 166-71	2.2	10
101	Drug-induced agranulocytosis: impact of different fcgamma receptor polymorphisms?. <i>Journal of Clinical Psychopharmacology</i> , 2005 , 25, 435-40	1.7	12
100	Endothelial nitric oxide synthase Glu298Asp gene polymorphism, blood pressure and hypertension in a general population sample. <i>Journal of Hypertension</i> , 2005 , 23, 1361-6	1.9	30
99	Identification and functional analysis of genetic variants of the human beta-glucuronidase in a German population sample. <i>Pharmacogenetics and Genomics</i> , 2005 , 15, 875-81	1.9	10
98	Endothelial nitric oxide synthase Glu(298)-->Asp polymorphism, carotid atherosclerosis and intima-media thickness in a general population sample. <i>Clinical Science</i> , 2005 , 109, 475-81	6.5	21
97	Mental and physical distress is modulated by a polymorphism in the 5-HT transporter gene interacting with social stressors and chronic disease burden. <i>Molecular Psychiatry</i> , 2005 , 10, 220-4	15.1	232
96	Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19. <i>Pharmacogenomics Journal</i> , 2005 , 5, 365-73	3.5	82
95	Metabolic gene polymorphisms and lung cancer risk in non-smokers. An update of the GSEC study. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2005 , 592, 45-57	3.3	43
94	Empfehlungen zur Diagnostik und Therapie der Schockformen der IAG Schock der DIVI. <i>Intensivmedizin Und Notfallmedizin</i> , 2005 , 42, 531-543		5
93	A functional serotonin transporter (SLC6A4) polymorphism modifies the association of smoking and diabetes with asymptomatic carotid atherosclerosis. <i>Thrombosis and Haemostasis</i> , 2005 , 93, 180-182	7	5
92	Endothelial NO synthase polymorphisms and postural tachycardia syndrome. <i>Hypertension</i> , 2005 , 46, 1103-10	8.5	30
91	Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?. <i>Antimicrobial Agents and Chemotherapy</i> , 2005 , 49, 1733-8	5.9	157
90	Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation. <i>Drug Metabolism and Disposition</i> , 2005 , 33, 896-904	4	129
89	Neonatale Pharmakologie 2005 , 643-659		
88	A functional serotonin transporter (SLC6A4) polymorphism modifies the association of smoking and diabetes with asymptomatic carotid atherosclerosis. <i>Thrombosis and Haemostasis</i> , 2005 , 93, 180-2	7	2
87	Pharmacogenetics-based new therapeutic concepts. <i>Drug Metabolism Reviews</i> , 2004 , 36, 617-38	7	27
86	Identification of twelve polymorphisms in the endothelin-1 gene by use of fluorescently labeled oligonucleotides and PCR with restriction fragment polymorphism analysis. <i>Clinical Chemistry</i> , 2004 , 50, 448-51	5.5	7

85	Decreased levels of dopamine D3 receptor mRNA in schizophrenic and bipolar patients. <i>Neuropsychobiology</i> , 2004 , 50, 305-10	4	54
84	Pharmacogenomics of heart failure -- focus on drug disposition and action. <i>Cardiovascular Research</i> , 2004 , 64, 32-9	9.9	17
83	Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure. <i>European Journal of Clinical Pharmacology</i> , 2004 , 60, 17-21	2.8	16
82	Association of metabolic gene polymorphisms with tobacco consumption in healthy controls. <i>International Journal of Cancer</i> , 2004 , 110, 266-70	7.5	20
81	CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 75, 213-22	6.1	102
80	Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 76, 192-200	6.1	134
79	High DNA damage by benzo[a]pyrene 7,8-diol-9,10-epoxide in bronchial epithelial cells from patients with lung cancer: comparison with lung parenchyma. <i>Cancer Letters</i> , 2004 , 207, 157-63	9.9	56
78	Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis. <i>Journal of Clinical Psychopharmacology</i> , 2004 , 24, 613-7	1.7	45
77	Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms. <i>Pharmacogenetics and Genomics</i> , 2004 , 14, 381-5		71
76	The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. <i>Current Alzheimer Research</i> , 2004 , 1, 121-5	3	131
75	Influence of doxorubicin on gene expression and protein pattern in HeLa cells. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2004 , 42, 640-1	2	2
74	CYP1A1 alleles in women with focal nodular hyperplasia of the liver (FNH). <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2004 , 42, 78-82	2	
73	CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers: a pooled analysis. <i>Carcinogenesis</i> , 2003 , 24, 875-82	4.6	152
72	Functional significance of a hereditary adenine insertion variant in the 5'UTR of the endothelin-1 gene. <i>Pharmacogenetics and Genomics</i> , 2003 , 13, 445-51		34
71	Pharmacogenomics of Bioavailability and Elimination. <i>Methods and Principles in Medicinal Chemistry</i> , 2003 , 363-380	0.4	
70	Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States). <i>Cancer Causes and Control</i> , 2003 , 14, 339-46	2.8	83
69	Interaction of CA repeat polymorphism of the endothelial nitric oxide synthase and hyperhomocysteinemia in acute coronary syndromes: evidence of gender-specific differences. <i>Journal of Molecular Medicine</i> , 2003 , 81, 305-9	5.5	8
68	Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. <i>European Journal of Clinical Pharmacology</i> , 2003 , 59, 303-12	2.8	186

67	Beta 2-adrenergic receptor polymorphism and susceptibility to primary congenital and primary open angle glaucoma. <i>European Journal of Clinical Pharmacology</i> , 2003 , 59, 527-31	2.8	9
66	CYP1A1 T3801 C polymorphism and lung cancer: a pooled analysis of 2451 cases and 3358 controls. <i>International Journal of Cancer</i> , 2003 , 104, 650-7	7.5	121
65	Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. <i>Gastroenterology</i> , 2003 , 124, 26-33	13.3	266
64	Expression and localization of the multidrug resistance protein 5 (MRP5/ABCC5), a cellular export pump for cyclic nucleotides, in human heart. <i>American Journal of Pathology</i> , 2003 , 163, 1567-77	5.8	81
63	Polymorphisms in CYP1A1, GSTM1, GSTT1 and lung cancer below the age of 45 years. <i>International Journal of Epidemiology</i> , 2003 , 32, 60-3	7.8	98
62	Association between the N-acetylation genetic polymorphism and bronchial asthma. <i>British Journal of Clinical Pharmacology</i> , 2002 , 54, 671-4	3.8	16
61	MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. <i>British Journal of Clinical Pharmacology</i> , 2002 , 54, 610-6	3.8	114
60	Gender and smoking-related risk reduction of periodontal disease with variant myeloperoxidase alleles. <i>Genes and Immunity</i> , 2002 , 3, 102-6	4.4	35
59	Effect of levothyroxine administration on intestinal P-glycoprotein expression: consequences for drug disposition. <i>Clinical Pharmacology and Therapeutics</i> , 2002 , 72, 256-64	6.1	42
58	Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. <i>Clinical Pharmacology and Therapeutics</i> , 2002 , 72, 326-32	6.1	156
57	The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. <i>Clinical Pharmacology and Therapeutics</i> , 2002 , 72, 572-83	6.1	161
56	Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. <i>Clinical Pharmacology and Therapeutics</i> , 2002 , 72, 584-94	6.1	243
55	Expression and localization of P-glycoprotein in human heart: effects of cardiomyopathy. <i>Journal of Histochemistry and Cytochemistry</i> , 2002 , 50, 1351-6	3.4	87
54	CYP1A1 and GSTM1 genotypes affect benzo[a]pyrene DNA adducts in smokers: comparison with aromatic/hydrophobic adduct formation. <i>Carcinogenesis</i> , 2002 , 23, 1969-77	4.6	133
53	Expression of N-acetyltransferases in periodontal granulation tissue. <i>Journal of Dental Research</i> , 2002 , 81, 349-53	8.1	14
52	Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. <i>Pharmacogenetics and Genomics</i> , 2002 , 12, 535-41		270
51	Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic lupus erythematosus. <i>Pharmacogenetics and Genomics</i> , 2002 , 12, 559-63		26
50	Molecular-epidemiological aspects of carcinogenesis: the role of xenobiotic metabolizing enzymes. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2002 , 40, 562-3	2	

49	Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-jewish caucasian sample. <i>Archives of General Psychiatry</i> , 2001 , 58, 93-4		55
48	Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2001 , 69, 169-74	6.1	541
47	Co-expression of human cytochrome P4501A1 (CYP1A1) variants and human NADPH-cytochrome P450 reductase in the baculovirus/insect cell system. <i>Xenobiotica</i> , 2001 , 31, 345-56	2	27
46	Myeloperoxidase--463A variant reduces benzo[a]pyrene diol epoxide DNA adducts in skin of coal tar treated patients. <i>Carcinogenesis</i> , 2001 , 22, 1015-8	4.6	40
45	Differential metabolism of benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1 variants. <i>Carcinogenesis</i> , 2001 , 22, 453-9	4.6	93
44	Identification of six methylenetetrahydrofolate reductase (MTHFR) genotypes resulting from common polymorphisms: impact on plasma homocysteine levels and development of coronary artery disease. <i>Atherosclerosis</i> , 2001 , 154, 651-8	3.1	41
43	Role of Kozak sequence polymorphism of platelet glycoprotein Ibalpha as a risk factor for coronary artery disease and catheter interventions. <i>Journal of the American College of Cardiology</i> , 2001 , 38, 1023-7	15.1	27
42	The beta3-adrenergic receptor Trp64Arg mutation is not associated with coronary artery disease. <i>Metabolism: Clinical and Experimental</i> , 2001 , 50, 184-8	12.7	13
41	Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry. <i>Pharmacogenetics and Genomics</i> , 2001 , 11, 135-41		46
40	High CA repeat numbers in intron 13 of the endothelial nitric oxide synthase gene and increased risk of coronary artery disease. <i>Pharmacogenetics and Genomics</i> , 2000 , 10, 133-40		53
39	Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. <i>Pharmacogenetics and Genomics</i> , 2000 , 10, 519-30		49
38	Elevated serum leptin in patients with coronary artery disease: no association with the Trp64Arg polymorphism of the beta3-adrenergic receptor. <i>International Journal of Obesity</i> , 2000 , 24, 369-75	5.5	19
37	Co-trimoxazole-induced liver and renal failure. Case report. <i>European Journal of Clinical Pharmacology</i> , 2000 , 56, 191-3	2.8	11
36	The platelet glycoprotein Ia C807T polymorphism as risk factor for coronary catheter interventions. <i>Blood</i> , 2000 , 96, 2002-2003	2.2	6
35	Molecular genetics of cancer susceptibility. <i>Pharmacology</i> , 2000 , 61, 212-27	2.3	57
34	Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6. <i>Pharmacopsychiatry</i> , 2000 , 33, 218-20	2	33
33	How to manage individualized drug therapy: application of pharmacogenetic knowledge of drug metabolism and transport. <i>Clinical Chemistry and Laboratory Medicine</i> , 2000 , 38, 869-76	5.9	27
32	Hyperhomocysteinaemia and adverse events complicating coronary catheter interventions. <i>International Journal of Cardiology</i> , 2000 , 76, 211-7	3.2	6

31	A1166C polymorphism of the angiotensin II type 1 receptor gene and risk of adverse events after coronary catheter interventions. <i>American Heart Journal</i> , 2000 , 140, 170-5	4.9	12
30	Modulation of benzo[a]pyrene diol-epoxide-DNA adduct levels in human white blood cells by CYP1A1, GSTM1 and GSTT1 polymorphism. <i>Carcinogenesis</i> , 2000 , 21, 35-41	4.6	113
29	The G protein subunit beta3 and early complications after coronary catheter interventions. <i>Atherosclerosis</i> , 2000 , 153, 523-4	3.1	
28	Reduced procedural risk for coronary catheter interventions in carriers of the coagulation factor VII-Gln353 gene. <i>Journal of the American College of Cardiology</i> , 2000 , 36, 1520-5	15.1	17
27	The platelet glycoprotein Ia C807T polymorphism as risk factor for coronary catheter interventions. <i>Blood</i> , 2000 , 96, 2002-2003	2.2	
26	Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000 , 97, 3473-8	11.5	1017
25	Genetic determinants of drug-induced agranulocytosis: potential risk of olanzapine?. <i>Pharmacopsychiatry</i> , 1999 , 32, 110-2	2	28
24	Implication of arylamine N-acetyltransferase (NAT2) polymorphism on levels of tumour markers CEA, AFP, CA 125, CA 19.9, and CA 15.3. <i>Biomarkers</i> , 1999 , 4, 129-34	2.6	
23	Population frequency, mutation linkage and analytical methodology for the Arg16Gly, Gln27Glu and Thr164Ile polymorphisms in the beta2-adrenergic receptor among Turks. <i>British Journal of Clinical Pharmacology</i> , 1999 , 48, 761-4	3.8	37
22	Paraoxonase 1 mutations in a Turkish population. <i>Toxicology and Applied Pharmacology</i> , 1999 , 157, 174-74.6	4.6	29
21	Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1). <i>Biochemical Pharmacology</i> , 1999 , 58, 1759-64	6	89
20	Arylamine N-acetyltransferase activity in man. <i>Drug Metabolism Reviews</i> , 1999 , 31, 489-502	7	75
19	A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter interventions: a case-controlled study. <i>Lancet, The</i> , 1999 , 353, 708-12	4.0	77
18	Association of arylamine N-acetyltransferases NAT1 and NAT2 genotypes to laryngeal cancer risk. <i>Pharmacogenetics and Genomics</i> , 1999 , 9, 103-112		4.0
17	Mutations in the human paraoxonase 1 gene: frequencies, allelic linkages, and association with coronary artery disease. <i>Pharmacogenetics and Genomics</i> , 1999 , 9, 755-61		43
16	Pitfalls in N-acetyltransferase 2 genotyping. <i>Pharmacogenetics and Genomics</i> , 1999 , 9, 123-7		57
15	High frequency of CYP1A1 mutations in a Turkish population. <i>Archives of Toxicology</i> , 1998 , 72, 215-8	5.8	34
14	Polymorphisms in xenobiotic conjugation and disease predisposition. <i>Toxicology Letters</i> , 1998 , 102-103, 173-83	4.4	43

13	CYP1A1 mutations 4887A, 4889G, 5639C and 6235C in the Polish population and their allelic linkage, determined by peptide nucleic acid-mediated PCR clamping. <i>Pharmacogenetics and Genomics</i> , 1997 , 7, 303-7		25
12	Arylamine N-acetyltransferase (NAT2) genotypes in a Turkish population. <i>Pharmacogenetics and Genomics</i> , 1997 , 7, 327-31		27
11	N-Acetyltransferase 2 (NAT2) and Glutathione S-Transferase μ (GSTM1) in Bladder-cancer Patients in a Highly Industrialized Area. <i>International Journal of Occupational and Environmental Health</i> , 1997 , 3, 105-110		23
10	Peptide nucleic acid-mediated polymerase chain reaction clamping allows allelic allocation of CYP1A1 mutations. <i>Analytical Biochemistry</i> , 1997 , 250, 256-7	3.1	12
9	NAT2*12A (803A-->G) codes for rapid arylamine n-acetylation in humans. <i>Pharmacogenetics and Genomics</i> , 1996 , 6, 257-9		28
8	Polymorphic enzymes of xenobiotic metabolism as modulators of acquired P53 mutations in bladder cancer. <i>Pharmacogenetics and Genomics</i> , 1996 , 6, 535-45		27
7	Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase gene in the Polish population. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 59, 376-82	6.1	35
6	Occupational history and genetic N-acetyltransferase polymorphism in urothelial cancer patients of Leverkusen, Germany. <i>Scandinavian Journal of Work, Environment and Health</i> , 1996 , 22, 332-8	4.3	37
5	Effects of a heterogeneous set of xenobiotics on RNA synthesis of yeast cells. <i>Ecotoxicology and Environmental Safety</i> , 1995 , 30, 252-8	7	2
4	Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3'flanking region. <i>The Clinical Investigator</i> , 1994 , 72, 240-8		74
3	Effects of a heterogeneous set of xenobiotics on growth and plasma membranes of mammalian and fungal cell cultures. <i>Ecotoxicology and Environmental Safety</i> , 1993 , 26, 113-26	7	16
2	Interaction of xenobiotics on the glucose-transport system and the Na ⁺ /K ⁺ -ATPase of human skin fibroblasts. <i>Ecotoxicology and Environmental Safety</i> , 1991 , 21, 38-46	7	20
1	Correlation between the lipophilicity of substituted phenols and their inhibition of the Na ⁺ /K ⁺ -ATPase of Chinese hamster ovary cells. <i>Toxicology</i> , 1989 , 58, 197-210	4.4	18